Caladrius Biosciences, Inc. (NASDAQ:CLBS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The brokerage currently has a $4.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 10.98% from the company’s previous close.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Several other research analysts have also weighed in on CLBS. HC Wainwright set a $7.00 target price on Caladrius Biosciences and gave the stock a “buy” rating in a research report on Friday. ValuEngine raised Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 10th.
Shares of Caladrius Biosciences (CLBS) traded down 1.38% on Tuesday, hitting $4.28. The stock had a trading volume of 6,413 shares. The company’s 50-day moving average price is $4.19 and its 200 day moving average price is $4.67. Caladrius Biosciences has a 12-month low of $2.65 and a 12-month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.08. Caladrius Biosciences had a negative return on equity of 742.11% and a negative net margin of 84.10%. On average, equities research analysts expect that Caladrius Biosciences will post ($2.36) earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of CLBS. KCG Holdings Inc. raised its position in shares of Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 15,501 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Caladrius Biosciences by 149.2% in the fourth quarter. Renaissance Technologies LLC now owns 72,652 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 43,500 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Caladrius Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after buying an additional 4,163 shares during the last quarter. 6.64% of the stock is currently owned by institutional investors.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
